Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Presbyopia in Breast Cancer Survivors

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00271661
First received: December 30, 2005
Last updated: December 8, 2011
Last verified: December 2011

December 30, 2005
December 8, 2011
August 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00271661 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Presbyopia in Breast Cancer Survivors
Presbyopia in Breast Cancer Survivors

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

primary care clinic

Presbyopia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2006
Not Provided

Inclusion Criteria:

  • ages 45-60
  • ability to understand and provide written consent in English

Exclusion Criteria:

  • blindness
  • visual defects leading to accommodative failure
  • severe myopia
  • recurrent breast cancer
Both
45 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00271661
BR-1-0072, ETHICS 22007
No
Not Provided
AHS Cancer Control Alberta
Not Provided
Principal Investigator: John Mackey, Dr. AHS Cancer Control Alberta
AHS Cancer Control Alberta
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP